TY706 Crystal Form A Stability via Controlled Crystallization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing form of the compound TY706 is unstable in appearance and purity, making it unsuitable for direct use as a pharmaceutical raw material due to fluctuations in physical form and purity levels during solvent evaporation, which complicates its use in treating gout and hyperuricemia.
Innovation Solution
A stable crystal form (crystal form A) of TY706 is developed, characterized by specific X-ray diffraction peaks and DSC analysis, which is produced through refluxing the compound in a solvent and subsequent cooling and filtration, ensuring consistent appearance and high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound TY706 is separated from solution by evaporation of solvent, then the compound can be obtained in solid form, but the physical form and appearance fluctuate from batch to batch making it difficult to maintain constant state
Solution Approach 1:
The patent applies parameter changes by controlling crystallization conditions including solvent type, temperature, pH value, and addition rate to obtain a stable crystal form (Form A) of TY706. This resolves the contradiction by transforming the amorphous or fluctuating solid obtained by simple evaporation into a well-defined crystal structure with consistent appearance and properties across batches.
Solution Approach 2:
The patent utilizes phase transitions through controlled crystallization from solution to transform the compound from an amorphous or unstable solid state into a stable crystal form. The crystallization process involves nucleation and crystal growth phases that produce consistent physical form and appearance, resolving the batch-to-batch variability issue.
2Productivity
If the compound TY706 is separated from solution by evaporation of solvent, then the compound can be obtained quickly, but the purity of the solid fluctuates greatly making pharmaceutical raw material preparation difficult
Solution Approach 1:
The patent applies preliminary action by performing crystallization before final product isolation. The crystallization step pre-purifies the compound by incorporating impurities into the mother liquor rather than having them co-evaporate with the product. This preliminary purification action ensures high and consistent purity while maintaining efficient production.
Solution Approach 2:
The crystallization process exploits phase transitions to separate the pure compound from impurities. As the solution cools or solvent evaporates during controlled crystallization, the pure compound crystallizes out while impurities remain in solution, achieving both high purity and consistent quality across batches.
3Stability of the object's composition
If a stable crystal form is developed through controlled crystallization, then appearance and purity are maintained consistently, but additional processing steps are required
Solution Approach 1:
The patent merges the purification and form stabilization steps into a single crystallization operation. The controlled crystallization process simultaneously achieves impurity removal, consistent appearance, and stable physical form, eliminating the need for separate purification and drying steps that would otherwise be required.
Solution Approach 2:
The patent optimizes crystallization parameters (solvent selection, temperature profile, pH control, addition rate) to achieve stable crystal formation in a single step. By carefully controlling these parameters, the process achieves both purification and form stabilization without requiring multiple sequential operations, thus limiting the increase in process complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form A of TY706 maintains stability over multiple batches, exhibits high purity, and demonstrates improved storage stability, making it suitable for pharmaceutical use with enhanced industrial practicality and efficacy in treating gout and hyperuricemia.
Implementation Method 1
A stable crystal form (crystal form A) of TY706 is developed, characterized by specific X-ray diffraction peaks and DSC analysis, which is produced through refluxing the compound in a solvent and subsequent cooling and filtration
Implementation Method 2
its powder X-ray diffraction (PXRD) pattern expressed by 2θ degree using Cu-Kα radiation has diffraction peaks at 18.432±1, 19.846±1, 20.207±1, 20.327±1, 22.341±1, 22.735±1, 25.654±1, 26.119±1, 26.617±1 and 33.159±1
Implementation Method 3
The differential scanning calorimetry (DSC) analysis curve of the crystal form A of the compound TY706 of the present invention has an endothermic peak at 189.30° C.
Data Source
AI summary
The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.


